Top 100 medical and healthcare startups in USA
Nov 18, 2025
Like
19
1
Funding: $50.6M
Knownwell is a plug-and-play platform designed to consolidate data from various sources.
Knownwell is a plug-and-play platform designed to consolidate data from various sources.
2
Funding: $15M
Bevel is a next-gen holistic wellness app unifying nutrition, sleep, recovery, strain, and stress tracking.
Bevel is a next-gen holistic wellness app unifying nutrition, sleep, recovery, strain, and stress tracking.
3
Funding: $9.5M
RIIG is a risk intelligence and cybersecurity solutions company, that focuses on improving organizational cybersecurity resilience.
RIIG is a risk intelligence and cybersecurity solutions company, that focuses on improving organizational cybersecurity resilience.
4
Funding: $543M
Lyell Immunopharma is developing a CAR-T cell therapy for colorectal cancer. The therapy targets tumors expressing the guanylate cyclase-C (GCC) protein receptor. GCC is expressed in more than 95% of colorectal cancer cases and in most cases of pancreatic adenocarcinoma. Lyell's genetic reprogramming technologies aim to slow T-cell depletion and generate more potent T-cells with enhanced, sustained anti-tumor activity in the immunosuppressive tumor microenvironment.
Lyell Immunopharma is developing a CAR-T cell therapy for colorectal cancer. The therapy targets tumors expressing the guanylate cyclase-C (GCC) protein receptor. GCC is expressed in more than 95% of colorectal cancer cases and in most cases of pancreatic adenocarcinoma. Lyell's genetic reprogramming technologies aim to slow T-cell depletion and generate more potent T-cells with enhanced, sustained anti-tumor activity in the immunosuppressive tumor microenvironment.
5
Funding: $185.2M
Arthrosi Therapeutics is a biotechnology company that focuses on drug discovery and development.
Arthrosi Therapeutics is a biotechnology company that focuses on drug discovery and development.
6
Funding: $75M
Neok is a spin-off of Korean biotech ABL, that paired its antibody skills with linker-payload technology to build a pipeline of ADCs. Neok was started with two ADC-candidates from ABL and plans to test them and deliver the first human data in 2027. The drugs target thoracic, gastrointestinal and gynecological cancers via ROR1, EGFR and MUC1 proteins. The expression of these proteins by some healthy cells makes on-target, off-tumor toxicity a concern for drugs that engage the receptor. But, in theory, Neok's bispecific design (which is fine-tuned for each target antigen pair) could improve safety. This dual-targeting strategy has the potential to target a wider range of tumors, overcome drug resistance.
Neok is a spin-off of Korean biotech ABL, that paired its antibody skills with linker-payload technology to build a pipeline of ADCs. Neok was started with two ADC-candidates from ABL and plans to test them and deliver the first human data in 2027. The drugs target thoracic, gastrointestinal and gynecological cancers via ROR1, EGFR and MUC1 proteins. The expression of these proteins by some healthy cells makes on-target, off-tumor toxicity a concern for drugs that engage the receptor. But, in theory, Neok's bispecific design (which is fine-tuned for each target antigen pair) could improve safety. This dual-targeting strategy has the potential to target a wider range of tumors, overcome drug resistance.
7
Funding: $48.1M
TransCode Therapeutics is an RNA oncology company that develops and commercializes drugs for the treatment of metastatic cancer.
TransCode Therapeutics is an RNA oncology company that develops and commercializes drugs for the treatment of metastatic cancer.
8
Funding: $25.4M
Arya's AI-powered digital agents automate crucial post-acute care workflows, such as caregiver scheduling, compliance tracking and hiring management.
Arya's AI-powered digital agents automate crucial post-acute care workflows, such as caregiver scheduling, compliance tracking and hiring management.
9
Funding: $20.5M
Marble Health provides access to personalized therapy to help teens in their mental health journey.
Marble Health provides access to personalized therapy to help teens in their mental health journey.
10
Funding: $4.3M
Alleviate Health is an AI-enabled patient recruitment company for clinical trials
Alleviate Health is an AI-enabled patient recruitment company for clinical trials
11
Funding: $200M
Soufflé Therapeutics has potent, precise, and safe medicines can be designed and developed for all diseases.
Soufflé Therapeutics has potent, precise, and safe medicines can be designed and developed for all diseases.
13
Funding: $77.1M
MD Integrations is a telemedicine company that provides virtual healthcare services.
MD Integrations is a telemedicine company that provides virtual healthcare services.
15
Funding: $315M
Star Therapeutics mission is to develop therapies for people living with serious bleeding disorders and other diseases in hematology and immunology
Star Therapeutics mission is to develop therapies for people living with serious bleeding disorders and other diseases in hematology and immunology
16
Funding: $37.6M
Visana Health offers a digital health program focused on improving the quality of life for women.
Visana Health offers a digital health program focused on improving the quality of life for women.
17
Funding: $172M
Wugen is developing off-the-shelf cellular therapies targeting solid tumors and hematologic malignancies
Wugen is developing off-the-shelf cellular therapies targeting solid tumors and hematologic malignancies
18
Funding: $100M
Ollin is dedicated to advancing novel therapeutic candidates that target a broader spectrum of biology to improve outcomes for patients with severe, vision-threatening conditions.
Ollin is dedicated to advancing novel therapeutic candidates that target a broader spectrum of biology to improve outcomes for patients with severe, vision-threatening conditions.
19
Funding: $4.6M
Helex is revolutionizing genomic medicine and advances in treating genetic kidney diseases. It designed lipid nanoparticle technology for targeted drug delivery and an intelligent drug design platform that enables de-risked, scalable and affordable therapeutics. Therapeutic payloads are directed to specific organs and cells beyond the liver filter. The technology is said to minimize immune response and eliminate the risk of insertional mutagenesis linked with viral vectors. Also it has greater scalability than viral vectors due to their simpler production process.
Helex is revolutionizing genomic medicine and advances in treating genetic kidney diseases. It designed lipid nanoparticle technology for targeted drug delivery and an intelligent drug design platform that enables de-risked, scalable and affordable therapeutics. Therapeutic payloads are directed to specific organs and cells beyond the liver filter. The technology is said to minimize immune response and eliminate the risk of insertional mutagenesis linked with viral vectors. Also it has greater scalability than viral vectors due to their simpler production process.
20
Funding: $141M
Antiva Biosciences is a biopharmaceutical company developing therapeutics for the treatment of diseases caused by HPV infection.
Antiva Biosciences is a biopharmaceutical company developing therapeutics for the treatment of diseases caused by HPV infection.
